BioMarin Pharmaceuticals
BMRN
BMRN
514 hedge funds and large institutions have $16.1B invested in BioMarin Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 43 funds opening new positions, 191 increasing their positions, 187 reducing their positions, and 76 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
514
Holders Change
-39
Holders Change %
-7.05%
% of All Funds
8.2%
Holding in Top 10
14
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+27.27%
% of All Funds
0.22%
New
43
Increased
191
Reduced
187
Closed
76
Calls
$139M
Puts
$86.9M
Net Calls
+$52.3M
Net Calls Change
+$62.2M
Top Buyers
| 1 |
Barclays
London,
United Kingdom
|
+$258M |
| 2 |
Nomura Holdings
Tokyo,
Japan
|
+$251M |
| 3 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$76.2M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$70.2M |
| 5 |
BlackRock
New York
|
+$52.4M |
Top Sellers
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$112M |
| 2 |
CG
Carmignac Gestion
Paris,
France
|
-$96.6M |
| 3 |
Capital Research Global Investors
Los Angeles,
California
|
-$65.3M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$52.8M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$47.4M |
